目标公司为一家于2009年12月31日于中国注册成立的有限公司。思妍丽创立于1996年，是目标公司旗下 中国高端美容服务行业的标杆品牌。秉持科技赋能、效果导向的护肤核心理念，思妍丽精心研发高端院 线护肤产品，专注为高线城市女性提供专业护肤与美容体验。根据弗若斯特沙利文数据，以2024年收入 计，目标公司旗下思妍丽品牌位列中国第三大的美容服务品牌。截至2025年6月30日，目标公司在全国 48个城市运营163家生活美容门店(包括直营门店118家及加盟门店45家)及19家医疗美容门诊，2024年超 过90%的总收入来自其位于中国前20个一线和新一线城市的门店。 收购事项是本集团继2024年成功收购奈瑞儿后又一重要里程碑，将重塑中国高线城市高端美容行业竞争 格局。于交割后，本集团门店网络将迅速扩张，门店数量将达致734家，同时带动会员基数实现显著增 长;依托独特的"双美+双保健"商业模式优势，本集团将推动美丽田园的行业龙头地位的巩固与市场占有 率的拓展实现双重跃升。 美丽田园医疗健康(02373)发布公告，于2025年10月15日(联交所交易时段前)，本公司、上海美丽田园医 疗健康、SYL Holding及上海安妍 ...

收购事项是本集团继2024年成功收购奈瑞儿后又一重要里程碑，将重塑中国高线城市高端美容行业竞争 格局。于交割后，本集团门店网络将迅速扩张，门店数量将达致734家，同时带动会员基数实现显著增 长;依托独特的"双美+双保健"商业模式优势，本集团将推动美丽田园的行业龙头地位的巩固与市场占有 率的拓展实现双重跃升。 于交割后，本集团将全面赋能目标公司：依托连锁企业管理、客户全生命周期管理、医疗服务升级， AI数智化转型及供应链整合五大核心能力。该强强联合将最大化协同效应，快速释放目标公司价值潜 力，驱动本集团收入与利润规模性提升，打开高质量发展的广阔空间。 于交割前，目标公司分别由SYL Holding持有74.0%权益及上海安妍持有26.0% 权益。于交割后，目标公 司将成为本公司间接全资附属公司。目标公司的业绩、资产及负债将并入本集团账目。 目标公司为一家于2009年12月31日于中国注册成立的有限公司。思妍丽创立于1996 年，是目标公司旗 下中国高端美容服务行业的标杆品牌。秉持科技赋能、效果导向的护肤核心理念，思妍丽精心研发高端 院线护肤产品，专注为高线城市女性提供专业护肤与美容体验。根据弗若斯特沙利文数据， ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告僅供參考之用，並不構成收購、購買或認購本公司任何證券之邀請或要約。 Beauty Farm Medical and Health Industry Inc. 美麗田園醫療健康產業有限公司 * （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：2373） 有關涉及根據特別授權發行對價股份 收購目標公司100%已發行股份之主要交易 財務顧問 收購事項 董事會欣然宣佈，於2025年10月15日（聯交所交易時段前），本公司、上海美麗田 園醫療健康、SYL Holding及上海安妍訂立股份購買協議，據此，（其中包括） SYL Holding及上海思妍（均作為賣方）有條件同意出售，而本公司及上海美麗田 園醫療健康（均作為買方）有條件同意收購上海思妍麗實業100%已發行股份，對 價為人民幣1,250.0百萬元（相當於約1,369.2百萬港元）。 – 1 – 作為對價的一部分，對價股份 ...

来源：瑞恩资本RyanbenCapital | | | 33家香港上市 [医疗服务企业] 涨幅排行榜 | | | | --- | --- | --- | --- | --- | | | ┣市公司 | 上市代码 | 2025.09.30 收市价 (港元) | 本年涨幅 | | 1 | 脑动极光-B | 06681.HK | 8.58 | 166.46% | | 2 | 麦迪卫康 | 02159.HK | 1.23 | 136.54% | | 3 | 雍禾医疗 | 02279.HK | 2.05 | 127.78% | | 4 | 美丽田园医疗健康 | 02373.HK | 35.92 | 101.80% | | 5 | 佰泽医疗 | 02609.HK | 7.83 | 85.55% | | 6 | 复星医药 | 02196.HK | 25.78 | 82.58% | | 7 | 康 外球 | 09960.HK | 1.46 | 23.73% | | 8 | 天安卓健 | 00383.HK | 0.90 | 23.29% | | ਰੇ | 环球医疗 | 02666.HK | 6.07 | 22.38% | | 1 ...

公司名稱: 美麗田園醫療健康產業有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02373 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.000005 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 10,000,000,000 | USD | | 0.000005 USD | | 50,000 | 本月底法定/註冊股本總額： ...

Core Viewpoint - Huachuang Securities reports that Meili Tianyuan Medical Health (02373) is a leading company in the domestic beauty and medical beauty service sector, with a strong brand reputation and operational capabilities. The company is expected to see performance growth due to deepening digital transformation, improved industry chain layout, and store expansion [1] Financial Overview - For the first half of 2025, the company reported revenue of 1.46 billion (up 28% year-on-year) and a net profit attributable to shareholders of 160 million (up 35%). Adjusted net profit reached 190 million (up 38%) [2] - The gross margin was 49.3% (up 2 percentage points), and the net margin was 11.7% (up 0.6 percentage points). The expense ratios for sales, management, and R&D were 17.2%, 16.2%, and 1.4%, respectively [2] Business Segmentation - Revenue breakdown: 55% from beauty services (51% from direct stores and 5% from franchises), 34% from medical beauty, and 11% from sub-health services. - Beauty services generated 810 million (up 30%) with a gross margin of 42.1% (up 2 percentage points) [3] - Medical beauty services generated 500 million (up 13%) with a gross margin of 56.9% (up 2 percentage points) [3] - Sub-health services generated 150 million (up 108%) with a gross margin of 63.1% (up 9 percentage points) [3] Operational Data - The company continues to expand its brand influence, with stable growth in store and membership numbers. - Beauty: 238 direct stores (down 1 from the end of 2024) and 276 franchise stores (unchanged), with membership increasing by 46% to 112,000 [4] - Medical beauty: 27 stores (down 1) [4] - Sub-health: 11 stores (unchanged) [4] Digital Transformation and Supply Chain - The company is accelerating its digital transformation by building online capabilities for customers, business, and organization, enhancing operational efficiency and customer service experience. Additionally, it is investing in upstream supply chains to ensure stable supply and cost advantages for core products [5] Team and Service Innovation - The core management and technical team remains stable, providing strong support for the company's development. The company continues to innovate in services by launching new beauty, medical beauty, and sub-health adjustment projects to meet diverse consumer needs, with a focus on expanding store presence in first- and second-tier cities [6]

Core Viewpoint - Meili Tianyuan Medical Health (02373) is a leading company in the domestic beauty and medical beauty service sector, with strong brand reputation and operational capabilities. The company is expected to see performance growth driven by deepening digital transformation, improved industry chain layout, and store expansion [1] Financial Overview - For the first half of 2025, the company reported revenue of 1.46 billion (up 28% year-on-year) and a net profit attributable to shareholders of 160 million (up 35%). Adjusted net profit reached 190 million (up 38%) [2] - The gross margin was 49.3% (up 2 percentage points), and the net margin was 11.7% (up 0.6 percentage points). The expense ratios for sales, management, and R&D were 17.2%, 16.2%, and 1.4%, respectively [2] Business Segmentation - Revenue breakdown: 55% from beauty services (51% from direct stores and 5% from franchises), 34% from medical beauty, and 11% from sub-health services. - Beauty services generated 810 million (up 30%) with a gross margin of 42.1% (up 2 percentage points) [3] - Medical beauty services generated 500 million (up 13%) with a gross margin of 56.9% (up 2 percentage points) [3] - Sub-health services generated 150 million (up 108%) with a gross margin of 63.1% (up 9 percentage points) [3] Operational Data - The company continues to expand its brand influence, with stable growth in store and membership numbers. - Beauty: 238 direct stores (down 1 from the end of 2024) and 276 franchise stores (unchanged), with membership increasing by 46% to 112,000 [4] - Medical beauty: 27 stores (down 1) [4] - Sub-health: 11 stores (unchanged) [4] Strategic Initiatives - The company is accelerating its digital transformation, enhancing online capabilities for customers, business, and organization to improve operational efficiency and customer service experience [5] - The company is also investing in upstream supply chains to ensure stable supply and cost advantages for core products and consumables, laying a solid foundation for long-term business development [5] Team and Innovation - The core management and technical teams remain stable, providing strong support for the company's development. The company continues to innovate in services, launching new beauty, medical beauty, and sub-health adjustment projects to meet diverse consumer needs [6] - Store expansion is focused on increasing presence in first- and second-tier cities to broaden market coverage [6]

美麗田園醫療健康產業有限公司 * (於開曼群島註冊成立的有限公司） Stock Code 股份代號：02373 INTERIM REPORT 2025 中期報 告 The character images in this picture are generated by DouBao AI 此圖片中人物部分由豆包AI生成 *For identification purposes only 僅供識別 美麗田園醫療健康產業有限公司 * CONTENTS 目錄 2 Corporate Information 公司資料 4 Financial Summary 財務概要 6 Management Discussion and Analysis 管理層討論及分析 30 Other Information 其他資料 52 Interim Condensed Consolidated Statements of Profit or Loss 中期簡明綜合損益表 53 Interim Condensed Consolidated Statements of Comprehensive Income 中期簡明綜合全面收益表 54 ...

Group 1 - The core viewpoint of the report is that Meili Tianyuan Medical Health (02373) is expected to maintain strong financial performance, with projected revenues of 3.05 billion, 3.41 billion, and 3.76 billion RMB for 2025-2027, and net profits of 320 million, 380 million, and 440 million RMB respectively [1] - The company achieved record high adjusted net profit in H1 2025, with revenues, net profit, and adjusted net profit reaching 1.46 billion, 170 million, and 190 million RMB respectively, representing year-on-year growth of 28%, 36%, and 38% [1] - The operating cash flow for H1 2025 was 410 million RMB, an increase of 84% year-on-year, with cash and cash equivalents amounting to 2 billion RMB, up 28% [1] Group 2 - The beauty and health services segment generated 810 million RMB in revenue, a year-on-year increase of 30%, while the medical beauty services segment achieved 500 million RMB, growing by 13% [1] - The sub-health medical services segment saw a remarkable revenue increase of 108%, reaching 150 million RMB, with the number of outpatient clinics expanding to 11 [1] - The Women's Health Center, a key part of the sub-health medical business, reported a revenue growth of 173% in H1 2025 [1] Group 3 - The company increased its stake in Nairu to 90%, enhancing profitability, with Nairu's revenue reaching 280 million RMB in H1 2025 and adjusted net profit margin rising from 6.5% to 10.4% [2] - Nairu, recognized as the "First Brand of Intelligent Beauty and Health" by Frost & Sullivan, is implementing an AI-driven transformation project called "Intelligent Beauty and Health 2.0 System" [2] Group 4 - The company has announced a "Capital Market Value Enhancement Plan" aimed at increasing shareholder returns, optimizing capital structure, and promoting sustainable development, with a total of 300 million RMB in dividends declared over the past three years [3] - The first dividend payment from the shareholder return plan is scheduled to be distributed by September 26, 2025, at a rate of 0.52 HKD per share [3]

Core Viewpoint - The company maintains its financial forecast for Meili Tianyuan Medical Health (02373), projecting revenues of 3.05 billion, 3.41 billion, and 3.76 billion RMB for 2025-2027, with net profits of 320 million, 380 million, and 440 million RMB respectively, assigning a target price of 45 HKD for 2025 based on a 30x PE ratio [1] Financial Performance - In H1 2025, the company achieved record high adjusted net profits of 1.9 billion RMB, with total revenues of 14.6 billion RMB, reflecting year-on-year growth of 28%, 36%, and 38% respectively [3] - Operating cash flow reached 4.1 billion RMB, an increase of 84% year-on-year, with cash and cash-equivalent assets totaling 2 billion RMB, up 28% [3] Business Segmentation - The beauty and wellness services segment generated 8.1 billion RMB in revenue, a 30% increase year-on-year, while medical beauty services brought in 5 billion RMB, growing 13% [3] - The sub-health medical services segment saw a remarkable revenue increase of 108%, reaching 1.5 billion RMB, with the number of outpatient clinics expanding to 11 [3] - The Women's Care Center, a key part of the sub-health medical business, reported a 173% year-on-year revenue growth in H1 2025 [3] Strategic Acquisitions - The company increased its stake in Nairu to 90% by acquiring an additional 20% share, resulting in enhanced profitability, with Nairu's revenue reaching 2.8 billion RMB and adjusted net profit margin rising from 6.5% to 10.4% [4] Shareholder Returns - The company has announced a "Capital Market Value Enhancement Plan" aimed at improving shareholder returns, optimizing capital structure, and promoting sustainable development, with a total of 300 million RMB in dividends declared over the past three years [5]